Pfizer to Use Sigma-Aldrich's ddRNAi Gene Silencing Tech | GenomeWeb
NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has granted Pfizer non-exclusive rights to its DNA-directed RNAi technology.
The agreement will allow Pfizer’s to use Sigma’s ddRNAi at any of its worldwide operations, Sigma said.
Sigma said it has exclusively licensed ddRNAi applications from Australian company Benitec and Australia’s Commonwealth Scientific and Industrial Research Organization.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.